If you would like to be considered for a clinical trial you will require a referral from your current treating team.
Visit the Joining a Clinical Trial page for referral information.
For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.
Clinical Trials Enquiry Coordinator
Business hours, Mon to Friday between 9am - 2pm
Open and Recruiting Clinical Trials
TCD17197
An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Trial ID
NCT05086315
Cancer type
Acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplasia
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
VICTORY
A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation.
Trial ID
NCT05005299
Cancer type
Acute leukaemia, myelodysplastic syndrome and chronic lymphocytic leukaemia
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
KER050-MD-201
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Trial ID
NCT04419649
Cancer type
Myelodysplastic syndromes
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
AMLM23
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Trial ID
NCT03839771
Cancer type
Acute myeloid leukemia and myelodysplastic syndrome
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
D9470C00001
A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies
Trial ID
NCT06179511
Cancer type
CD123-positive haematological malignancies
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the ClinicalTrials.gov.
If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.